Skip to content
Companies

NurExone Biologic

Exosome drug for acute spinal cord injury

Raised to date

$2.2M

of $4.4M offered across 3 Form D filings

Still open
$2.2M
Investors
1
Last filed
Jul 2, 2026

About

NurExone Biologic Inc. is a publicly traded biopharmaceutical company based in Canada, specializing in the development of innovative treatments for neurological injuries, particularly focusing on spinal cord injuries. Their research and products aim to address the significant need for effective recovery solutions for patients suffering from acute spinal cord trauma.

NurExone's unique focus on non-invasive exosome-based therapies, like ExoPTEN, sets it apart from traditional treatment methodologies.

Funding

$3.8M round, first sold Apr 2025$1.6M sold$2.1M still openApr 20252026
Now
  • EquityFiled Jul 2, 2026Form D
    $442K/ $442K
  • EquityFiled Aug 27, 2025Form D
    $148K/ $243K
  • EquityFiled Apr 22, 2025Form D
    $1.6M/ $3.8M

Product

ExoPTEN

Regenerative Medicine

ExoPTEN is an exosome-loaded nanodrug designed to facilitate neuron regeneration and restore motor, sensory, and functional abilities in patients who have recently experienced acute spinal cord injuries.

  • Intranasal administration for non-invasive treatment
  • Uses proprietary ExoTherapy platform to produce exosomes
  • Targets neuronal recovery and regeneration

Built for

Patients with acute spinal cord injuries

People on file